Immunological monitoring of VZV vaccination in patients with renal failure versus healthy individuals

Completed

• Conditions: herpes zoster; shingles; 10047438; 10038430

• Registration Number: NL-OMON37984
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

- Age of patient and donor is 50 years or older
- Patients on waitinglist for living-related kidney transplantation and their donors
- Patients at least 1 month prior to kidney transplantation
- Patient is VZV seropositive before vaccination
- Patient is capable of understanding the purpose and risks of the study, fully informed and given written informed consent

Exclusion Criteria

- Use of immunosuppresion (inhalation corticosteroids are allowed)
- Neomycine allergy
- Fever
- Immunodeficiency due to e.g. acute/chronic leukaemia, lymphoma or HIV
- Active tuberculosis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>VZV-specific IgG and IgM levels from baseline to endpoint (1 year after<br /><br>vaccination)<br /><br>Percentage of VZV-reactive memory CD4+ and CD8+ T-cells from baseline to<br /><br>endpoint</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Detection of VZV positive PCR in blood, transplantation will be delayed until<br /><br>PCR is negative</p><br>